💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Phenprocoumon

CHEMBL1465 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
280.3 g/mol
LogP
3.6
Phase
4

Phenprocoumon is a long-acting oral anticoagulant of the 4-hydroxycoumarin class that inhibits vitamin K epoxide reductase, thereby preventing the regeneration of reduced vitamin K needed for the carboxylation of clotting factors II, VII, IX, and X. It is widely used in several European countries for the prevention and treatment of thromboembolic disorders including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

الوزن الجزيئي

280,3000 g/mol

LogP

3,60

TPSA

46,50 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Melanoma Systemic Lupus Erythematosus Stroke Deep Vein Thrombosis / Pulmonary Embolism Atrial Fibrillation

آلية العمل

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H16O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
الروابط القابلة للدوران

                        
3

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Phenprocoumon is a long-acting oral anticoagulant of the 4-hydroxycoumarin class that inhibits vitamin K epoxide reductase, thereby preventing the regeneration of reduced vitamin K needed for the carboxylation of clotting factors II, VII, IX, and X. It is widely used in several European countries for the prevention and treatment of thromboembolic disorders including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Phenprocoumon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1465.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 54680692.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.